Author:
He Xiao-yan,Xiong Xiao-jiao,Liu Mei-jun,Liang Jing-tao,Liu Fu-you,Xiao Jing-yi,Wu Li-juan
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 2019;65:37–55.
2. Shan L, Liu Z, Ci L, Shuai C, Lv X, Li J. Research progress on the anti-hepatic fibrosis action and mechanism of natural products. Int Immunopharmacol 2019;75:105765.
3. Altamirano-Barrera A, Barranco-Fragoso B, Mendez-Sanchez N. Management strategies for liver fibrosis. Ann Hepatol 2017;16:48–56.
4. Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015;49:690–696.
5. Li M, Wang ZQ, Zhang L, Zheng H, Liu DW, Zhou MG. Burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China, 1990–2016: findings from the Global Burden of Disease Study 2016. Biomed Environ Sci 2020;33:1–10.